Rani Therapeutics’ (RANI) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Rani Therapeutics (NASDAQ:RANI) in a research note published on Friday morning,Benzinga reports. The firm currently has a $11.00 target price on the stock. HC Wainwright also issued estimates for Rani Therapeutics’ Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2030 earnings at ($0.30) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rani Therapeutics in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.33.

Rani Therapeutics Price Performance

Shares of RANI stock opened at $0.81 on Friday. The stock’s fifty day moving average price is $1.27 and its 200 day moving average price is $1.32. Rani Therapeutics has a 1-year low of $0.39 and a 1-year high of $3.87. The company has a market cap of $98.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.39.

Rani Therapeutics (NASDAQ:RANI) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). The business had revenue of $1.46 million during the quarter, compared to the consensus estimate of $5.00 million. As a group, equities research analysts anticipate that Rani Therapeutics will post -1.01 earnings per share for the current year.

Institutional Trading of Rani Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kestra Private Wealth Services LLC grew its stake in Rani Therapeutics by 12.7% during the 4th quarter. Kestra Private Wealth Services LLC now owns 254,812 shares of the company’s stock valued at $344,000 after purchasing an additional 28,670 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Rani Therapeutics in the fourth quarter worth about $40,000. Virtu Financial LLC acquired a new stake in shares of Rani Therapeutics during the fourth quarter worth about $69,000. CWA Asset Management Group LLC lifted its holdings in shares of Rani Therapeutics by 80.0% during the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company’s stock worth $75,000 after purchasing an additional 66,667 shares during the period. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Rani Therapeutics in the fourth quarter valued at approximately $93,000. Institutional investors and hedge funds own 30.19% of the company’s stock.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.